Johnson & Johnson’s Janssen Pharmaceuticals Unit has received FDA approval for its new diabetes drug, Invokana (canagliflozin). The drug is the first in a new class of Type 2 Diabetes meds dubbed SGLT2 inhibitors; drugs in this class work by reducing the amount of sugar absorbed in the body and flushing any excess out through the urine.
Invokana has the potential to offer an innovative means to battle the disease (which affects approx. 26 million Americans) but also showed serious risks, including heart attack and stroke, in clinical trial patients.
According to several published reports, Invokana reportedly caused a variety of side effects in clinical trial patients, including:
According to the FDA, Janssen is required to complete 5 post marketing studies on Invokana, including:
Thomas J. Henry are leaders in the area of drug and product liability litigation. Our Defective Drug and Products Division have extensive knowledge and resources in order to represent our clients efficiently and aggressively. The Defective Drug and Products Division represent a multitude of people who are battling against manufacturers of medical devices and/ or defective pharmaceuticals.
If you or a loved one have been injured by or have developed serious side-effects from the use of defective medications or medical devices, contact Thomas J. Henry immediately. We represent clients/victims all over the country. We are available 24/7, nights and weekends.